JPWO2020223221A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223221A5 JPWO2020223221A5 JP2021564298A JP2021564298A JPWO2020223221A5 JP WO2020223221 A5 JPWO2020223221 A5 JP WO2020223221A5 JP 2021564298 A JP2021564298 A JP 2021564298A JP 2021564298 A JP2021564298 A JP 2021564298A JP WO2020223221 A5 JPWO2020223221 A5 JP WO2020223221A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- cancer
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 85
- 102000036639 antigens Human genes 0.000 claims description 85
- 108091007433 antigens Proteins 0.000 claims description 85
- 229940127121 immunoconjugate Drugs 0.000 claims description 57
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 52
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 49
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- -1 sulfosuccinimide ester Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical group CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 claims description 6
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002254 cytotoxic agent Substances 0.000 claims description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 4
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 4
- BLTRCTCTKKJRIC-UHFFFAOYSA-N 1-(cyclohexylmethyl)pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CC1CCCCC1 BLTRCTCTKKJRIC-UHFFFAOYSA-N 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000002628 peritoneum cancer Diseases 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 claims description 3
- ORKSBKSSOSUJOY-UHFFFAOYSA-N 2,5-dioxo-1-[4-(pyridin-2-yldisulfanyl)pentanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O ORKSBKSSOSUJOY-UHFFFAOYSA-N 0.000 claims description 2
- OWDQCSBZQVISPN-UHFFFAOYSA-N 2-[(2,5-dioxopyrrolidin-1-yl)amino]-4-(2-iodoacetyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O OWDQCSBZQVISPN-UHFFFAOYSA-N 0.000 claims description 2
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 claims description 2
- JNWSNQJRTXEHIV-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfopentanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CC(C)SSC1=CC=CC=N1 JNWSNQJRTXEHIV-UHFFFAOYSA-N 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 102000053180 human FOLR1 Human genes 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 108010056243 alanylalanine Proteins 0.000 description 4
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 3
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 3
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 3
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 description 1
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 description 1
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 1
- 102100035144 Folate receptor beta Human genes 0.000 description 1
- 102100035143 Folate receptor gamma Human genes 0.000 description 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
- VHLZDSUANXBJHW-QWRGUYRKSA-N Gln-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-QWRGUYRKSA-N 0.000 description 1
- MRVYVEQPNDSWLH-XPUUQOCRSA-N Gln-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O MRVYVEQPNDSWLH-XPUUQOCRSA-N 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 1
- 101001023204 Homo sapiens Folate receptor beta Proteins 0.000 description 1
- 101001023202 Homo sapiens Folate receptor gamma Proteins 0.000 description 1
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 1
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 description 1
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193434A JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840297P | 2019-04-29 | 2019-04-29 | |
| US62/840,297 | 2019-04-29 | ||
| US201962879864P | 2019-07-29 | 2019-07-29 | |
| US62/879,864 | 2019-07-29 | ||
| PCT/US2020/030245 WO2020223221A1 (en) | 2019-04-29 | 2020-04-28 | Biparatopic fr-alpha antibodies and immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193434A Division JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022530524A JP2022530524A (ja) | 2022-06-29 |
| JP2022530524A5 JP2022530524A5 (https=) | 2023-05-10 |
| JPWO2020223221A5 true JPWO2020223221A5 (https=) | 2023-05-10 |
| JP7585230B2 JP7585230B2 (ja) | 2024-11-18 |
Family
ID=73028723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564298A Active JP7585230B2 (ja) | 2019-04-29 | 2020-04-28 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
| JP2024193434A Active JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193434A Active JP7844591B2 (ja) | 2019-04-29 | 2024-11-05 | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11396543B2 (https=) |
| EP (1) | EP3962935A4 (https=) |
| JP (2) | JP7585230B2 (https=) |
| KR (1) | KR20220004687A (https=) |
| CN (1) | CN114222756A (https=) |
| AU (1) | AU2020265568B2 (https=) |
| CA (1) | CA3138272A1 (https=) |
| IL (1) | IL287451A (https=) |
| MA (1) | MA55818A (https=) |
| SG (1) | SG11202111109UA (https=) |
| TW (2) | TWI872065B (https=) |
| WO (1) | WO2020223221A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911499A1 (en) * | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| WO2020223221A1 (en) * | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
| AU2022207985A1 (en) * | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| WO2022256507A1 (en) * | 2021-06-04 | 2022-12-08 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
| KR20240159839A (ko) | 2022-03-09 | 2024-11-06 | 아스트라제네카 아베 | FRα에 대한 결합 분자 |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| WO2025252094A1 (zh) * | 2024-06-05 | 2025-12-11 | 长春金赛药业有限责任公司 | 靶向叶酸受体α(FRα)的抗体、双特异性抗体和偶联物，及其制备和用途 |
| US20260001950A1 (en) * | 2024-07-01 | 2026-01-01 | Medicovestor, Inc. | Methods of enhancing efficacy of immunoconjugates using paired human antibodies targeted at non-overlapping b-cell epitopes on the same antigen |
| WO2026020031A2 (en) * | 2024-07-18 | 2026-01-22 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| CN103037900B (zh) * | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| AU2011323124C1 (en) | 2010-11-05 | 2016-09-22 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| IL281714B2 (en) | 2011-04-01 | 2023-11-01 | Immunogen Inc | Methods for increasing the effectiveness of FOLR1 cancer therapy |
| US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
| HUE049693T2 (hu) | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására |
| CA2911499A1 (en) | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| IL298044B2 (en) | 2013-10-08 | 2024-11-01 | Immunogen Inc | Dosing regimens of anti-FOLR1 immunoconjugate |
| EP3153178A4 (en) | 2014-06-06 | 2017-12-20 | Kyowa Hakko Kirin Co., Ltd. | Method for treating cancer patients using folr1 targeted drug and antifolate, and drug |
| CN106999604B (zh) | 2014-09-02 | 2021-08-03 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| KR20250171447A (ko) * | 2017-02-28 | 2025-12-08 | 이뮤노젠 아이엔씨 | 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체 |
| GB201707864D0 (en) | 2017-05-16 | 2017-06-28 | Inst Of Cancer Research: Royal Cancer Hospital | Platinum-reistant cancer treatment |
| SG11202001348WA (en) | 2017-09-05 | 2020-03-30 | Immunogen Inc | Methods for detection of folate receptor 1 in a patient sample |
| JP2020534332A (ja) | 2017-09-22 | 2020-11-26 | イミュノジェン， インコーポレイテッド | カチオン交換クロマトグラフィーを使用した三重軽鎖抗体の分離 |
| MA51629A (fr) | 2018-01-12 | 2020-11-18 | Immunogen Inc | Procédés de production, purification et formulation de conjugués anticorps-médicaments |
| WO2020223221A1 (en) * | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
| WO2022256507A1 (en) * | 2021-06-04 | 2022-12-08 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
-
2020
- 2020-04-28 WO PCT/US2020/030245 patent/WO2020223221A1/en not_active Ceased
- 2020-04-28 US US16/860,822 patent/US11396543B2/en active Active
- 2020-04-28 CN CN202080037442.7A patent/CN114222756A/zh active Pending
- 2020-04-28 KR KR1020217037919A patent/KR20220004687A/ko active Pending
- 2020-04-28 TW TW109114175A patent/TWI872065B/zh active
- 2020-04-28 MA MA055818A patent/MA55818A/fr unknown
- 2020-04-28 AU AU2020265568A patent/AU2020265568B2/en active Active
- 2020-04-28 TW TW113151397A patent/TW202515623A/zh unknown
- 2020-04-28 CA CA3138272A patent/CA3138272A1/en active Pending
- 2020-04-28 EP EP20798751.2A patent/EP3962935A4/en active Pending
- 2020-04-28 SG SG11202111109UA patent/SG11202111109UA/en unknown
- 2020-04-28 JP JP2021564298A patent/JP7585230B2/ja active Active
-
2021
- 2021-10-20 IL IL287451A patent/IL287451A/en unknown
-
2022
- 2022-06-10 US US17/838,016 patent/US11834498B2/en active Active
-
2023
- 2023-10-24 US US18/493,623 patent/US20240182560A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193434A patent/JP7844591B2/ja active Active
-
2025
- 2025-08-12 US US19/297,369 patent/US20260061058A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2765098C2 (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| JP6412114B2 (ja) | 抗体薬物コンジュゲート | |
| US20200289661A1 (en) | Cd48 antibodies and conjugates thereof | |
| ES2895623T3 (es) | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes | |
| ES2526433T3 (es) | Inmunoconjugados dirigidos a CD138 y usos de los mismos | |
| CA3176248A1 (en) | Charge variant linkers | |
| US20240261422A1 (en) | Anthracycline antibody conjugates | |
| CN110167355A (zh) | 多药抗体药物偶联物 | |
| US10618935B2 (en) | Antibody-drug conjugate (ADC) and method for forming the same | |
| US12006370B2 (en) | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy | |
| CN102065891A (zh) | 新型协同效应 | |
| US20210260212A1 (en) | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy | |
| JPWO2020223221A5 (https=) | ||
| JP2018138538A (ja) | リンカー−薬物およびこれを用いた抗体−薬物複合体（ａｄｃ） | |
| JP2026000988A (ja) | Ａｌｋ５阻害剤複合体およびその使用 | |
| IL273384B2 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| CA3125751A1 (en) | Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy | |
| RU2015106946A (ru) | Антитела к рецептору эндотелина типа в (etbr) и их иммуноконъюгаты | |
| JP7816796B2 (ja) | 複合体およびその使用 | |
| CN119156231A (zh) | 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法 | |
| US12403185B2 (en) | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy | |
| RU2021130453A (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2023100251A (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство | |
| JPWO2023104188A5 (https=) |